Declaration of interests
NC reports grants or contracts from AstraZeneca and GSK (paid to institution), payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, MSD, GSK, Eisai, AbbVie, Pharma&, and Corcept; support for attending meetings or travel from GSK, AstraZeneca, and AbbVie; participation on a Data Safety Monitoring Board or Advisory Board from Roche, AstraZeneca, MSD, GSK, Immunogen, Eisai, Oncxerna, Nuvation Bio, Gilead, Regeneron, Novocure, Seagen, AbbVie, Lilly, BeOne, and Biontech; medical writing assistance from MSD; and participation in the Scientific Committee ACTO and the Member Nomination Committee ESMO (unpaid). EZ reports grants or contracts from MSD, NCI, DoD, and OCRA; consulting fees from MSD, AbbVie, NextCure, Iovance, 92Biotech, Takeda Oncology, and Apellis; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events for AstraZeneca; and participation on a Data Safety Monitoring Board or Advisory Board for MSD. ER reports grants or contracts from AstraZeneca, Gilead, MSD, and Roche (paid to institution); and support for attending meetings or travel and participation in a Data Monitoring Committee from Philogen. AS reports Advisory Board and Data Safety Monitoring Board participation, and speaker's honorarium, from GSK, Eisai, and MSD. CG reports consulting fees from GSK, Gilead, MSD, and Adium; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, MSD, and Adium; and participation on a Data Safety Monitoring Board or Advisory Board from GSK, Gilead, and Adium. KH reports research contracts from Daiichi Sankyo, Eisai, MSD, and Takeda; consulting fees from Chugai, Fuji, and Kyowa Kirin; advisory board fees from Eisai, Takeda, MSD, Regeneron, Roche, Genmab, Sanofi, GSK, and Zymeworks; honoraria from Daiichi Sankyo, AstraZeneca, Chugai, Eisai, Fuji, Genmab, MSD, Takeda, Sanofi, Kyowa Kirin, Kaken, GSK, and Regeneron. MM-M reports research funding from MSD; grants or contracts from Eli Lilly, MSD, and Fortrea (paid to institution); Advisory Board and speaker fees from Eli-Lilly, Roche, Merck GA, MSD, and GSK; and support for attending meetings or travel from Novartis, Merck GA, and Servier. JRK reports grants or contracts from AstraZeneca, Novartis, Philips, Dutch Cancer Society, and Bontius Stichting/LUF (paid to institution); consulting fees from AstraZeneca, Eisai, GSK, Lilly, MSD, Novartis, and Daiichi Sankyo (paid to institution); payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Eisai, GSK, and MSD (paid to institution); support for attending meetings or travel from Daiichi Sankyo (paid to institution); and participation on a Data Safety Monitoring Board or Advisory Board for DSMB, TEIPP, and Alison. ACdM reports grants or contracts, paid to institution, from Amgen, AstraZeneca, Bristol Myers, Squibb, Clovis Oncology, GSK, MSD, Novartis, Regeneron, and Roche; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Bristol Myers Squibb, GSK, MSD, Novartis, Adium, Daiichi, Pfizer, and AbbVie; support for attending meetings or travel from MSD, Daiichi, and AbbVie; and participation on a Data Safety Monitoring Board or Advisory Board from AstraZeneca, Bristol Myers Squibb, GSK, MSD, Novartis, Roche, and Daiichi. PRD reports consulting fees from MSD, Astellas, and Ipsen; support for attending meetings or travel from Ipsen and MSD; and stock or stock options from Mural Oncology and UCB. J-WK reports a leadership or fiduciary role in the Executive Board of the Asia-Pacific Gynecologic Cancer Trials Group. JS reports research funding from AstraZeneca, Bayer, Clovis Oncology, GSK, Iqvia, Lilly, MSD, Mural, Roche Pharma, and Tesaro (paid to institution); consulting fees from AstraZeneca, Bayer Vital, Bristol Myers, Clovis Oncology, Daiichi Sankyo, Eisai, Encare, Immunogen, Intuitive Surgical, Karyopharm Therapeutics, Merck/Pfizer, MSD, Mundipharma, Novocure, Oncoinvent, PharmaMar, Roche Pharma, Sanofi-Aventis Deutschland, Seagen, and Tubulis; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AMGEN, AstraZeneca, Bayer, Clovis Oncology, Corcept Therapeutics, Daiichi Sankyo, Eisai, Esteve Pharmaceuticals, GSK, Hexal, Incyte Biosciences, Jenapharm, Kyowa Kirin, Medtronic Covidien, Novartis Pharma, Oncoinvent, Pharma&, PharmaMar, Phytolife Nutrition, Roche Pharma, and Vifor Pharma; support for attending meetings or travel from AstraZeneca, GSK, Roche Pharma, Novocure, Immunogen, Incyte, MSD, and Eisai; participation on a Data Safety Monitoring Board or Advisory Board for Immunogen, Incyte, GSK, AstraZeneca, Clovis, Novocure, Bristol Myers Squibb, MSD, Bayer, and PharmaMar; leadership or fiduciary role in European Society of Gynecological Oncology, North-Eastern German Society of Gynecological Oncology, Pan-Arabian Research Society for Gynecological Oncology, Deutsch-Türkische Gynäkologengesellschaft, Deutsche Stiftung Eierstockkrebs, Arbeitsgemeinschaft Gynäkologische Onkologie, and Charité Comprehensive Cancer Center; medical writing assistance from MSD; unpaid participation in editorial boards for International Journal of Gynecological Cancer, Journal of the Turkish-German Gynecological Association, Anticancer Research, Archives of Gyencology and Obstetrics, Research and Treatment, Annals of Gynecology and Obstetrics Research, Journal of Hematology & Multiple Myeloma, and guest editorship for Cancers. M-EP reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, AstraZeneca, AbbVie, Tecnofarma, Dr Reddy's, and MSD; and support for attending meetings or travel from GSK, AstraZeneca, Roche, AbbVie, and MSD. SH reports participation on a Data Safety Monitoring Board or Advisory Board and advisory or consulting fees from AstraZeneca, Eisai, MSD, GSK, and AbbVie. CZ reports honoraria for participation in the Delphi study from Daiichi Sankyo and AstraZeneca; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, MSD, Eisai, GSK, Menarini Stemline, Exact Sciences, and Gilead; support for attending meetings or travel from Roche, Novartis, Pfizer, AstraZeneca, Daiichi Sankyo, MSD, Eisai, GSK, and Gilead; and participation on a Data Safety Monitoring Board or Advisory Board for Roche, Novartis, Pfizer, Lilly, AstraZeneca, Daiichi Sankyo, MSD, Eisai, GSK, Menarini Stemline, Exact Sciences, and Gilead. BJM reports consulting fees from AstraZeneca, BioNtech, Corcept, DSI, Eisai, Eli Lilly, Genmab/Seagen/Pfizer, GOG Foundation, GSK, Immunogen/Abbvie, Incyte, Karyopharm, MSD, Mersana, Mural/Alkermes, Myriad, Natera, Novartis, Novocure, OncoC4, Panavance, Pharma&, ProfoundBio/Genmab, Regeneron, Roche/Genentech, Sutro, Tubulis, Verastem, Zentalis, and Zymeworks; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, DSI, Eisai, GSK, Immunogen/AbbVie, and MSD. RLC reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, MSD, GSK, Karyopharm, Faeth, Genmab, and DSI; participation on a Data Safety Monitoring Board or Advisory Board for AstraZeneca, Genmab/Seagen, GSK, Immunogen, Panavance, Profoundbio, and Roche/Genentech; and leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, as a steering committee member for AstraZeneca, GSK, MSD, Roche-Genentech, and Verastem; as a trial chair for Immonogen/AbbVie; as a coordinating principal investigator for Karyopharm; and as a principal investigator for AbbVie, Genmab, Immunogen, MSD, and Roche/Genentech. TDLMR reports grants or contracts from GSK (paid to institution); consulting fees from GSK, AstraZeneca, Eisai, MSD, Pfizer, Novartis, Gilead, AbbVie, Sanofi, and Regeneron; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from GSK, AstraZeneca, MSD, Pfizer, Gilead, and AbbVie; support for attending meetings or travel from Roche, Gilead, and MSD; and participation on a Data Safety Monitoring Board or Advisory Board for MSD. XP, KY, and AMB are employees of Merck Sharp & Dohme, a subsidiary of Merck & Co, Rahway, NJ, USA, who may own stock or hold stock options in Merck & Co, Rahway, NJ, USA. All other authors declare no competing interests.
